AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34370839
Drug: Immunotherapies (3/49
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapies (3/49 drugs)
Trial: 34370839
Drug: Cytotoxics (12/49
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxics (12/49 drugs)
Trial: 34370839
Drug: Miscellaneous (10/49
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miscellaneous (10/49 drugs)
Trial: 34370839
Drug: Anticancer drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticancer drugs reporting
Trial: 34370839
Drug: New signals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New signals from drugs
Trial: 34371366
Drug: quavonlimab 75
RxNorm normalized name: Quavonlimab
DrugBank: Quavonlimab (DB16422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quavonlimab 75 mg Q6W plus pembrolizumab 200 mg Q3W
Trial: 34373186
Drug: rabbit anti-thymocyte
RxNorm normalized name: Rabbit anti-thymocyte immunoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabbit anti-thymocyte globulin (ATG) 3 mg/kg on day 8 post-transplant
Trial: 34373186
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ATG treatment)
Trial: 34373952
Drug: Daily values
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily values or trends of clinical parameters associated with acute organ dysfunction, acid-base derangement, coagulation impairment, or systemic inflammation.
Trial: 34374622
Drug: Global Evaluation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Global Evaluation of Treatment Effectiveness (GETE)
Trial: 34374848
Drug: No supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplementation for patients with calcemia ≥ 2.16 mmol/l and PTH ≥ 1.9 pmol/l
Trial: 34374848
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for patients with calcemia between 1.9 and 2.16 mmol/l and PTH > 4.7 pmol/l
Trial: 34374848
Drug: Calcemia between
RxNorm normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcemia between 1.9 and 2.16 mmol/l and PTH > 1.9 pmol/l
Trial: 34374848
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of corrected calcemia and PTH on POD1
Trial: 34375315
Drug: bNAb-derived CAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bNAb-derived CAR T cell therapy
Trial: 34375343
Drug: Universal testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal testing and treatment approach (HIV testing and ART initiation)
Trial: 34375394
Drug: Balanced solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced solution (n=5522)
Trial: 34375394
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution (n=5530)
Trial: 34376064
Drug: ESC 0/1h-hs-cTnT-algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESC 0/1h-hs-cTnT-algorithm with hs-cTnT change <7 ng/L
Trial: 34376064
Drug: ESC 0/1h-hs-cTnT-algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESC 0/1h-hs-cTnT-algorithm with hs-cTnT change ≥7 ng/L
Trial: 34376064
Drug: Novel derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel derived 0/3h-criteria for observe-zone patients with hs-cTnT concentration <15 ng/L and absolute change <4 ng/L
Trial: 34376064
Drug: Novel derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel derived 0/3h-criteria with absolute change ≥6 ng/L
Trial: 34376579
Drug: Isatuximab (CD38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isatuximab (CD38 monoclonal antibody)
Trial: 34376577
Drug: Itraconazole; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole; specific dosage and duration not mentioned
Trial: 34377216
Drug: Routine daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine daily stressors
Trial: 34377592
Drug: Autologous EBV-expanded
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous EBV-expanded cytotoxic T lymphocytes (CTLs) in combination with gemcitabine and carboplatin chemotherapy
Trial: 34379916
Drug: CIS43LS (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIS43LS (5 mg/kg, 20 mg/kg, 40 mg/kg)
Trial: 34379916
Drug: CIS43LS (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIS43LS (40 mg/kg)
Trial: 34380536
Drug: Iguratimod (IGU)
RxNorm normalized name: dextromethorphan
DrugBank: Iguratimod (DB12233)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Iguratimod (IGU) as induction therapy for 24 weeks
Trial: 34380536
Drug: Iguratimod (IGU)
RxNorm normalized name: dextromethorphan
DrugBank: Iguratimod (DB12233)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Iguratimod (IGU) as maintenance therapy for 24 weeks
Trial: 34380536
Drug: Cyclophosphamide as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide as induction therapy for 24 weeks
Trial: 34380536
Drug: Azathioprine as
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine as maintenance therapy for 24 weeks
Trial: 34380625
Drug: CCW702 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCW702 (a bispecific antibody)
Trial: 34380662
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks until disease progression/unacceptable toxicity
Trial: 34380663
Drug: Ipilimumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg intravenously every 2 weeks)
Trial: 34380979
Drug: 3HP treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3HP treatment (rifapentine plus isoniazid) delivered by RN/CHW program
Trial: 34380979
Drug: 3HP treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3HP treatment
Trial: 34381382
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy (MBCT), details on dosage and duration not available
Trial: 34382075
Drug: Endometrial progesterone
RxNorm normalized name: progesterone Vaginal Insert [Endometrin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial progesterone (P4) levels and 17α-hydroxyprogesterone levels measured after 5 days of vaginal treatment with micronised progesterone (400 mg/12 h) and oestradiol valerate (6 mg/day).
Trial: 34382365
Drug: pegargiminase (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegargiminase (36 mg/m) plus pemetrexed and cisplatin (ADIPemCis)
Trial: 34383370
Drug: Sorafenib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (150 mg/m² continuous oral twice daily) with Irinotecan (oral, once daily days 1-5, every 21 days)
Trial: 34383370
Drug: Sorafenib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (150 mg/m²)
Trial: 34383393
Drug: Electroconvulsive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive Therapy
Trial: 34383662
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (cognitive games on tablet computers and cycling on the ergometer sequentially on a non-VR platform)
Trial: 34383676
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (control group).
Trial: 34383682
Drug: Weekly patient-reported
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly patient-reported outcomes using Brief Psychiatric Rating Scale, Calgary Depression Scale, and Positive and Negative Syndrome Scale.
Trial: 34384079
Drug: 2 consecutive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 consecutive intracavernous injections of allogeneic Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs)
Trial: 34384227
Drug: Multimodal Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal Treatment Study of ADHD (MTA)
Trial: 34384460
Drug: Elevated suPAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated suPAR above 3 ng/ml
Trial: 34384460
Drug: Elevated suPAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated suPAR above 9 ng/ml
Trial: 34384490
Drug: Baseline procedures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline procedures including neurological and neuropsychological examinations; tau and amyloid positron emission tomography; magnetic resonance imaging and spectroscopy; lumbar puncture; blood and saliva collection; standardized self-report measures of neuropsychiatric, cognitive, and daily functioning.
Trial: 34385584
Drug: ZEN-3694 combined
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ZEN-3694 combined with CDK4/6 inhibitors
Trial: 34385584
Drug: ZEN-3694 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ZEN-3694 treatment
Trial: 34385708
Drug: Tumor-infiltrating lymphocytes
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor-infiltrating lymphocytes (TILs) administered with nivolumab
Trial: 34385708
Drug: TIL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIL treatment
Trial: 34386974
Drug: Thrombopoietin-receptor agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombopoietin-receptor agonists (TPO-RAs)
Trial: 34387119
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) therapy, 2 times a week for 6 weeks (total of 12 treatments)
Trial: 34387310
Drug: SARS-CoV-2 polymerase
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 polymerase chain reaction, immunoglobulin G (IgG) testing for 6 months
Trial: 34387310
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies detection
Trial: 34387570
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (bedside irrigation, primary closure, antibiotics, discharge with follow-up)
Trial: 34387570
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (surgical debridement, irrigation, and closure)
Trial: 34387648
Drug: BNT162b2 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 mRNA COVID-19 vaccine (2 doses, 21 days apart)
Trial: 34387648
Drug: BNT162b2 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 mRNA COVID-19 vaccine (in patients with B-NHL)
Trial: 34387648
Drug: BNT162b2 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 mRNA COVID-19 vaccine (in patients with i-B-NHL vs a-B-NHL)
Trial: 34387679
Drug: Cannabidiol, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol, 300 mg (150 mg twice per day) plus standard care
Trial: 34388386
Drug: Talazoparib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib (1 mg per day; or 0.75 mg per day in patients with moderate renal impairment)
Trial: 34388972
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) ß-1a, 3 doses of 125 μg by subcutaneous administration (days 1, 6, and 11)
Trial: 34389237
Drug: Novel osimertinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel osimertinib combination therapies (Group A)
Trial: 34389237
Drug: Non-biomarker selected
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-biomarker selected therapies (chemotherapy- or EGFR-TKI-based) (Group B)
Trial: 34389237
Drug: Local practice
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local practice treatment (Group C)
Trial: 34389568
Drug: Metabolic bariatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolic bariatric surgery (MBS), specifically vertical sleeve gastrectomy (VSG), details on dosage and duration not available.
Trial: 34389568
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical treatment approaches including lifestyle change, metformin, thiazolidinediones, or insulin, details on dosage and duration not available.
Trial: 34957480
Drug: Intramuscular plasmid
RxNorm normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular plasmid treatment
Trial: 34957480
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of plasmid
Trial: 34389618
Drug: GWN323 (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GWN323 (1500 mg every 3 weeks)
Trial: 34389618
Drug: GWN323 (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GWN323 (750 mg) + spartalizumab (300 mg every 3 weeks)
Trial: 34389618
Drug: GWN323 (single-agent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GWN323 (single-agent)
Trial: 34389618
Drug: GWN323 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GWN323 + spartalizumab (combination)
Trial: 34389694
Drug: 5-fluorouracil (5FU)-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (5FU)-based adjuvant chemotherapy
Trial: 34389930
Drug: Insulin pumps
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin pumps and CGM
Trial: 34390869
Drug: AAV8-RS1 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AAV8-RS1 gene replacement therapy administered intravitreally in a phase I/IIa trial
Trial: 34390869
Drug: AAV8-RS1 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AAV8-RS1 gene replacement therapy
Trial: 34391393
Drug: Cannabidiol 600
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol 600 mg (300 mg BID)
Trial: 34391393
Drug: Risperidone 4
RxNorm normalized name: risperidone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 4 mg (2 mg BID)
Trial: 34391480
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 (2.5-360 mg)
Trial: 34391480
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 (5 mg)
Trial: 34391480
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 (160 mg)
Trial: 34391480
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 (10 mg)
Trial: 34391480
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 (360 mg)
Trial: 34391791
Drug: Single high-sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-sensitive cardiac troponin I (hs-cTnI) measurement at admission, diagnostic cut-off <3 ng/L
Trial: 34391922
Drug: AFP (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFP (20 ng/mL or greater)
Trial: 34392453
Drug: GT0918 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GT0918 (500 mg QD)
Trial: 34393800
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment (doses not specified)
Trial: 34394782
Drug: Tiotropium/olodaterol 5/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium/olodaterol 5/5 µg fixed dose combination for 6 weeks
Trial: 34394782
Drug: Tiotropium/olodaterol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium/olodaterol treatment
Trial: 34395277
Drug: Preoperative systemic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative systemic treatment
Trial: 34395560
Drug: Subcutaneous Implantable
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD) implantation
Trial: 34396157
Drug: Trastuzumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab with ACE inhibitors and/or beta-blockers
Trial: 34396210
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist degarelix
Trial: 34396210
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist leuprolide
Trial: 34397042
Drug: Consecutive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consecutive therapy consisting of esomeprazole 40 mg or rabeprazole 20 mg twice daily, amoxicillin 1,000 mg twice daily, tetracycline 500 mg 4 times daily, and furazolidone 100 mg 3 times daily for the first 7 days, followed by colloidal bismuth pectin 200 mg twice daily for another 7 days.
Trial: 34397042
Drug: Consecutive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consecutive therapy including amoxicillin, tetracycline, and furazolidone.
Trial: 34397042
Drug: Resistance rates
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance rates to antibiotics in patients with available antimicrobial susceptibility testing results (51 patients).
Trial: 34397539
Drug: Symptomatic management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic management and traditional therapies for congestive heart failure
Trial: 34397707
Drug: Control of
RxNorm normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control of low-density lipoprotein cholesterol (LDL-C) < 2.6 mmol/l
Trial: 34397719
Drug: Triptorelin (Diphereline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (Diphereline, 3.75 mg intramuscular injection once every 28 days for up to 24 weeks) - Group A (1-3 injections)
Trial: 34397719
Drug: Triptorelin (Diphereline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (Diphereline, 3.75 mg intramuscular injection once every 28 days for up to 24 weeks) - Group B (4-6 injections)
Trial: 34397987
Drug: empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: empagliflozin (10 mg once daily)
Trial: 34397987
Drug: sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin (100 mg once daily)
Trial: 34398238
Drug: Interleukin-7 (IL-7)
RxNorm normalized name: interleukin-7
DrugBank: Interleukin-7 (DB11997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-7 (IL-7) administration to ICL patients
Trial: 34398588
Drug: Surgically Targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgically Targeted Radiation Therapy (STaRT) with GammaTile
Trial: 34398971
Drug: Chidamide-cladribine-gemcitabine-busulfan (ChiCGB)
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chidamide-cladribine-gemcitabine-busulfan (ChiCGB) combination as conditioning therapy after transplantation with autologous peripheral stem cells.
Trial: 34398971
Drug: Chidamide-cladribine-gemcitabine-busulfan (ChiCGB)
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chidamide-cladribine-gemcitabine-busulfan (ChiCGB) combination as conditioning therapy.
Trial: 34399737
Drug: Dignity Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dignity Therapy (DT) intervention
Trial: 34399811
Drug: Headache and
RxNorm normalized name: Flonase Headache and Allergy Relief
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Headache and nausea/vomiting combination
Trial: 34400137
Drug: Hysterectomy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hysterectomy and lymph node staging without adjuvant therapy
Trial: 34400337
Drug: Control groups
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control groups (HDS containing green tea without G cambogia and other HDS)
Trial: 34401374
Drug: Online cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online cognitive behavior therapy (CBT) targeting avoidance behavior, duration: 8 weeks, with therapist support